X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (119) 119
index medicus (68) 68
colorectal cancer (59) 59
humans (57) 57
colorectal neoplasms - drug therapy (47) 47
bevacizumab (40) 40
female (40) 40
male (40) 40
metastasis (38) 38
aged (36) 36
cancer (36) 36
colorectal neoplasms - pathology (36) 36
chemotherapy (33) 33
middle aged (32) 32
antineoplastic combined chemotherapy protocols - therapeutic use (29) 29
metastatic colorectal cancer (27) 27
colorectal neoplasms - genetics (26) 26
metastases (26) 26
adult (25) 25
cetuximab (24) 24
colorectal carcinoma (23) 23
camptothecin - analogs & derivatives (20) 20
colorectal neoplasms - mortality (20) 20
mutation (20) 20
neoplasm metastasis (20) 20
patients (20) 20
care and treatment (19) 19
irinotecan (19) 19
prognosis (18) 18
treatment outcome (18) 18
oxaliplatin (17) 17
research (17) 17
survival (17) 17
analysis (16) 16
camptothecin - administration & dosage (16) 16
disease-free survival (16) 16
therapy (16) 16
tumors (16) 16
1st-line treatment (15) 15
clinical trials (15) 15
panitumumab (15) 15
braf (13) 13
fluorouracil (13) 13
proto-oncogene proteins b-raf - genetics (13) 13
fluorouracil - administration & dosage (12) 12
hematology, oncology and palliative medicine (12) 12
kaplan-meier estimate (12) 12
kras (12) 12
leucovorin - administration & dosage (12) 12
receptor, epidermal growth factor - antagonists & inhibitors (12) 12
aged, 80 and over (11) 11
drug therapy (11) 11
genetic aspects (11) 11
leucovorin (11) 11
ras proteins - genetics (11) 11
retrospective studies (11) 11
angiogenesis inhibitors - therapeutic use (10) 10
antineoplastic combined chemotherapy protocols - administration & dosage (10) 10
adenocarcinoma - drug therapy (9) 9
angiogenesis (9) 9
antibodies, monoclonal, humanized - administration & dosage (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
folfoxiri (9) 9
liver neoplasms - drug therapy (9) 9
liver neoplasms - secondary (9) 9
organoplatinum compounds - administration & dosage (9) 9
proto-oncogene proteins - genetics (9) 9
proto-oncogene proteins p21 (9) 9
resistance (9) 9
antibodies, monoclonal - therapeutic use (8) 8
biomarkers (8) 8
confidence intervals (8) 8
follow-up studies (8) 8
usage (8) 8
5-fluorouracil (7) 7
antibodies, monoclonal - administration & dosage (7) 7
antibodies, monoclonal, humanized (7) 7
bevacizumab - administration & dosage (7) 7
digestive system diseases (7) 7
medical research (7) 7
monoclonal antibodies (7) 7
mutations (7) 7
open-label (7) 7
phase-iii (7) 7
proportional hazards models (7) 7
settore med/06 - oncologia medica (7) 7
single-nucleotide polymorphism (7) 7
survival analysis (7) 7
trial (7) 7
alleles (6) 6
antineoplastic agents - therapeutic use (6) 6
bevacizumab - therapeutic use (6) 6
camptothecin - therapeutic use (6) 6
cancer patients (6) 6
cancer therapies (6) 6
capecitabine (6) 6
cells (6) 6
combination (6) 6
efficacy (6) 6
fluorouracil - therapeutic use (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1306 - 1315
Summary Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab significantly improved... 
Hematology, Oncology and Palliative Medicine | TRIAL | CETUXIMAB | SURROGATE | LEUCOVORIN | ONCOLOGY | END-POINT | PROGRESSION-FREE SURVIVAL | RAS MUTATIONS | GUIDELINES | KRAS | FLUOROURACIL | Leucovorin - administration & dosage | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Angiogenesis Inhibitors - administration & dosage | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Angiogenesis Inhibitors - therapeutic use | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Bevacizumab - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Intention to Treat Analysis | Italy | Aged | Infusions, Intravenous | Mutation | Colorectal Neoplasms - pathology | Antimitotic agents | Cancer patients | Care and treatment | Patient outcomes | Analysis | Colorectal cancer | Leucovorin | Metastasis | Antineoplastic agents | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2014, Volume 371, Issue 17, pp. 1609 - 1618
In patients with metastatic colon cancer, fluorouracil, oxaliplatin, and irinotecan plus bevacizumab, as compared with fluorouracil and irinotecan plus... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | INFUSIONAL FLUOROURACIL | LEUCOVORIN | MANAGEMENT | PHASE-III | GUIDELINES | IRINOTECAN | OXALIPLATIN | CHEMOTHERAPY | FOLFIRI | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Bevacizumab | Fluorouracil - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Neoplasm Metastasis - drug therapy | Colorectal Neoplasms - drug therapy | Adult | Female | Leucovorin - therapeutic use | Liver Neoplasms - secondary | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Organoplatinum Compounds - adverse effects | Treatment outcome | Care and treatment | Analysis | Colorectal cancer | Dosage and administration | Leucovorin | Fluorouracil | Colorectal carcinoma | Diarrhea | Metastasis | Survival | Patients | Clinical outcomes | Metastases | Irinotecan | Stomatitis | Chemotherapy | Neurotoxicity | Oxaliplatin | Monoclonal antibodies | Vascular endothelial growth factor | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Clinical advances in hematology & oncology : H&O, ISSN 1543-0790, 08/2019, Volume 17, Issue 8, pp. 433 - 435
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 01/2011, Volume 103, Issue 1, pp. 21 - 30
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2017, Volume 23, Issue 10, pp. 2414 - 2422
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 03/2018, Volume 24, Issue 5, pp. 1082 - 1089
Purpose: Refining the selection of HER2-positive metastatic gastric cancer patient candidates for trastuzumab is a challenge of precision oncology. Preclinical... 
CELL LUNG-CANCER | BREAST-CANCER | EGFR MONOCLONAL-ANTIBODIES | GASTROESOPHAGEAL ADENOCARCINOMA | IMPACT | THERAPY | ONCOLOGY | COLORECTAL-CANCER | PHASE-III | GENOMIC ALTERATIONS | HER2 | Prospective Studies | Trastuzumab - pharmacokinetics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Male | Response Evaluation Criteria in Solid Tumors | Stomach Neoplasms - pathology | Case-Control Studies | Patient Selection | Aged, 80 and over | Adult | Female | Receptor, ErbB-2 - antagonists & inhibitors | Trastuzumab - pharmacology | Stomach Neoplasms - genetics | Trastuzumab - therapeutic use | Stomach Neoplasms - drug therapy | Antineoplastic Agents, Immunological - pharmacology | Drug Resistance, Neoplasm - genetics | Antineoplastic Agents, Immunological - therapeutic use | Progression-Free Survival | Survival Analysis | Aged | Biomarkers, Tumor - genetics | Mutation | Precision Medicine - methods | Impact prediction | Metastasis | Stomach cancer | Metastases | c-Met protein | Confidence intervals | Receptors | Alterations | Bioindicators | Amnesia | Protein-tyrosine kinase | Gastric cancer | Predictive control | Tyrosine | Epidermal growth factor receptors | Patients | ErbB-2 protein | 1-Phosphatidylinositol 3-kinase | Signaling | Experimental design | Biomarkers | PTEN protein | Trastuzumab | Tumors | Cancer | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 9, pp. 845 - 852
Summary Background The FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) regimen has been shown to be better than FOLFIRI (fluorouracil,... 
Hematology, Oncology and Palliative Medicine | LIVER METASTASES | INFUSIONAL FLUOROURACIL | LEUCOVORIN | K-RAS | PLUS IRINOTECAN | ONCOLOGY | CLINICAL-TRIALS | TUMOR RESPONSE | ORAL FLUOROPYRIMIDINES | BICC-C | CHEMOTHERAPY | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Bevacizumab | Antibodies, Monoclonal, Humanized | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Adenocarcinoma - drug therapy | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Organoplatinum Compounds - adverse effects | Adenocarcinoma - mortality | Chemotherapy | Oncology, Experimental | Colorectal cancer | Clinical trials | Metastasis | Research | Angiogenesis inhibitors | Drug therapy | Cancer | Medical research | Analysis | Medicine, Experimental | Index Medicus
Journal Article
Nature Medicine, ISSN 1078-8956, 07/2015, Volume 21, Issue 7, pp. 795 - 801
Journal Article
JAMA surgery, ISSN 2168-6254, 12/2018, Volume 153, Issue 12, pp. 1162 - 1163
Journal Article
Journal Article
Oncotarget, ISSN 1949-2553, 04/2019, Volume 10, Issue 29, pp. 2791 - 2792
Journal Article